Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA

Showing 15 posts of 1440 posts found.

Rethinking oncology trial endpoints with generalised pairwise comparisons

November 4, 2025
Research and Development EMA, FDA, Oncology, One2Treat, clinical trials, generalised pairwise comparisons, net treatment benefit, oncology

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …

Feature
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

October 14, 2025
Alto Neuroscience, FDA, schizophrenia

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) has received Fast Track designation …

News
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

September 1, 2025
FDA

The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and mNEXSPIKE, intended to target the …

News
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025
Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …

News
Photo of patient

FDA grants orphan drug designation to antibody-mediated rejection treatment

June 26, 2025
Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation

Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …

News

FDA approves Incyte’s new anal cancer treatment

May 20, 2025
Research and Development FDA, Incyte Corporation, Oncology, Orphan Drug Designation (ODD), Zynyz, fast track designation, priority review

The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat …

News

FDA approves diagnostic tool for MET-targeted lung cancer therapy

May 19, 2025
Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer

The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …

News

Medable unveils oncology trial platform aimed at reducing logistical hurdles

May 16, 2025
Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials

Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …

News
researchers

Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU

May 16, 2025
Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia

Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …

News

Kaerus Bioscience secures FDA approval for rare genetic disorder treatment

May 15, 2025
Research and Development FDA, Fragile X syndrome, Kaerus Bioscience, Orphan Drug Designation (ODD), Rare Diseases, Rare Pediatric Drug Designations (RPDD), genetic syndromes

Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug …

News

Thermosome secures FDA Orphan Drug Designation for soft tissue sarcoma therapy

May 12, 2025
Research and Development European Medicines Agency (EMA), FDA, Oncology, Thermosome

Thermosome has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead candidate, THE001, …

News

Genmab to submit FDA application for lymphoma therapy

May 2, 2025
Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics

Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …

News
blood_tests_pic

Mursla Bio’s platform for surveillance of liver cancer receives FDA approval

April 24, 2025
Industry Associations, Research and Development BDD, FDA, Mursla Bio, Oncology, hepatocellular carcinoma (HCC), liver disease

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to EvoLiver, Mursla Bio’s surveillance platform for …

News

Qfitlia approved by FDA to treat haemophilia A or B

March 31, 2025
Research and Development FDA, Haematology, Sanofi, haemophilia, pharma

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …

News

FDA grants fast track designation to chlamydia vaccine candidate

March 28, 2025
Research and Development FDA, Infections and infestations, Sanofi, chlamydia, vaccination

The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025